Landes Bioscience

www.landesbioscience.com

Supplemental Material to:

Ilana Chefetz, Ayesha B. Alvero, Jennie C. Holmberg, Noah Lebowitz, Vinicius Craveiro, Yang Yang-Hartwich, Gang Yin, Lisa Squillace, Marta Gurrea Soteras, Paulomi Aldo and Gil Mor

TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence

2013; 12(3)

http://dx.doi.org/10.4161/cc.23406

http://www.landesbioscience.com/journals/cc/article/23406

Legends to Supplementary Figures

S. Figure 1: **Expression of CD44 in recurrent EOC patients.** A high number of CD44 positive cells were detected by immunohistochemistry (brown staining) in EOC tumors from patients with recurrent disease. Representative sections from two patients are shown in A & B.

S. Figure 2: **Wound repair in CD44+ /MyD88+ EOC stem cells.** EOC stem cells were grown to complete confluence. Following wounding using the wound maker tool, repair was determined by wound width was quantified by Incucyte imaging system.

S. Figure 3: *In vitro* wound/repair model. CD44+.MyD88+ EOC stem cells were grown to full confluence prior to wounding. Cell pellet from different areas (WE, WB) and control were obtained.

S. Figure 4: TLR2 ligation by PGN activates NFκB. NFκB activity was measured in CD44+.MyD88+ EOC stem cells using a luciferase reporter construct, pBII-LUC containing two κB sites before a FOS essential promoter.

S. Figure 5 NFkB inhibition decreases IL-6 secretion. Effect of NFkB inhibitor BAY 11-7082 on IL-6 secretion level was evaluated after 24 hr by xMAP technology

Supplementary Movies:

Movie 1. In vitro wound/repair in CD44+/MyD88+ EOC stem cell cultures

Movie 2. CD44-/MyD88- EOC cells do not repair *in vitro* wound

Supplementary Fig. 1





Supplementary Fig. 2



Supplementary Fig. 3



Supplementary Fig. 4



Supplementary Fig. 5